Novo Holdings co-leads £90 million Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates

Novo Holdings United Kingdom United States of America Denmark

Funds will be used to build out Myricx Bio's proprietary payload platform and advance its pipeline through clinical proof of concept.Novo Holdings Venture Investments Partner Michael Bauer will join Myricx Board of Directors and Principal Max Klement will join Myricx Board as an Observer.This is the largest European biotech Series A financing this year.View original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-co-leads-90-million-114-million-series-a-financing-for-myricx-bio-to-advance-a-novel-payload-class-for-antibody-drug-conjugates-302190026.html